EA201200101A1 - Способ прогнозирования эффективности лекарственных соединений для пациента - Google Patents

Способ прогнозирования эффективности лекарственных соединений для пациента

Info

Publication number
EA201200101A1
EA201200101A1 EA201200101A EA201200101A EA201200101A1 EA 201200101 A1 EA201200101 A1 EA 201200101A1 EA 201200101 A EA201200101 A EA 201200101A EA 201200101 A EA201200101 A EA 201200101A EA 201200101 A1 EA201200101 A1 EA 201200101A1
Authority
EA
Eurasian Patent Office
Prior art keywords
predicting
drug compounds
patient
efficiency
tumor
Prior art date
Application number
EA201200101A
Other languages
English (en)
Other versions
EA021945B1 (ru
Inventor
Владимир Лазарь
Жан-Шарль Сория
Мишель Дюкрё
Томас Турс
Original Assignee
Уорлдуайд Иновейтив Нетуорк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уорлдуайд Иновейтив Нетуорк filed Critical Уорлдуайд Иновейтив Нетуорк
Publication of EA201200101A1 publication Critical patent/EA201200101A1/ru
Publication of EA021945B1 publication Critical patent/EA021945B1/ru

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Изобретение касается способа прогнозирования относительной эффективности множества лекарственных соединений при лечении опухоли у индивидуума, который включает описание молекулярных характеристик опухоли и расчет балльной оценки для множества лекарственных средств, преимущественно основанный на проценте дерегулированных генов-мишеней.
EA201200101A 2009-07-08 2010-07-06 Способ прогнозирования эффективности лекарственных соединений для пациента EA021945B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22379809P 2009-07-08 2009-07-08
PCT/EP2010/059648 WO2011003911A1 (en) 2009-07-08 2010-07-06 Method for predicting efficacy of drugs in a patient

Publications (2)

Publication Number Publication Date
EA201200101A1 true EA201200101A1 (ru) 2012-08-30
EA021945B1 EA021945B1 (ru) 2015-10-30

Family

ID=42790891

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200101A EA021945B1 (ru) 2009-07-08 2010-07-06 Способ прогнозирования эффективности лекарственных соединений для пациента

Country Status (14)

Country Link
US (2) US10095829B2 (ru)
EP (1) EP2452281B1 (ru)
JP (1) JP5773998B2 (ru)
CN (1) CN102473202B (ru)
AU (1) AU2010270227B2 (ru)
CA (1) CA2767659C (ru)
DK (1) DK2452281T3 (ru)
EA (1) EA021945B1 (ru)
ES (1) ES2763899T3 (ru)
IL (1) IL217338A (ru)
NZ (1) NZ597655A (ru)
SG (2) SG10201403896XA (ru)
WO (1) WO2011003911A1 (ru)
ZA (1) ZA201200872B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2666921C2 (ru) * 2013-06-20 2018-09-13 Тайхо Фармасьютикал Ко., Лтд. СПОСОБ ПРЕДСКАЗАНИЯ ТЕРАПЕВТИЧЕСКОЙ ЭФФЕКТИВНОСТИ ИНГИБИТОРА PI3K/AKT/mTOR НА ОСНОВАНИИ ЭКСПРЕССИИ PHLDA1 ИЛИ PIK3C2B

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
DK3147373T3 (da) 2010-07-27 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer
WO2012019191A2 (en) * 2010-08-06 2012-02-09 Cardiomems, Inc. Systems and methods for using physiological information
SG10201605210PA (en) 2012-01-31 2016-08-30 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
RU2509808C1 (ru) * 2012-10-30 2014-03-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53
US10709341B2 (en) 2012-11-21 2020-07-14 St. Jude Medical Luxembourg Holdings II S.a.r.l. Devices, systems, and methods for pulmonary arterial hypertension (PAH) assessment and treatment
US10262112B2 (en) * 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
WO2014137705A1 (en) * 2013-03-05 2014-09-12 The Board Of Trustees Of The Leland Stanford Junior University Assessing risk for encephalopathy induced by 5-fluorouracil or capecitabine
US9198908B2 (en) 2013-03-15 2015-12-01 St. Jude Medical Luxembourg Holdings Ii S.A.R.L. (“Sjm Lux Ii”) Methods for the treatment of cardiovascular conditions
RU2528247C2 (ru) * 2013-05-07 2014-09-10 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ оценки чувствительности клеток рака легкого к доксорубицину на основании уровней экспрессии маркерных генов и набор для его осуществления
ES2832886T3 (es) * 2013-08-19 2021-06-11 Cipherome Inc Método y sistema para seleccionar un fármaco sobre la base de la información del daño de proteína individual para prevenir los efectos secundarios de un fármaco
EP2881472A1 (en) * 2013-12-09 2015-06-10 Université Pierre et Marie Curie (Paris 6) A method of predicting a response to an anti-tumor treatment
AU2015249513A1 (en) * 2014-04-24 2016-10-06 Pfizer Inc. Cancer treatment
EP3766986B1 (en) * 2014-12-31 2022-06-01 Guardant Health, Inc. Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
EP3261008B1 (en) 2015-02-17 2021-09-08 Cipherome, Inc. Method for selecting anticancer agent based on protein damage information of individual to prevent anticancer agent side effects
WO2018078142A1 (en) * 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of fluorouracil (5-fu) in colorectal cancer (crc) therapy
CN113621706B (zh) * 2017-06-22 2024-05-10 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
RU2670656C9 (ru) * 2017-08-30 2018-12-12 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования роста опухоли в эксперименте
CN108053887A (zh) * 2017-11-02 2018-05-18 杭州英放生物科技有限公司 一种实体瘤疗效评估方法、电子设备、存储介质、系统
WO2019168426A1 (ru) * 2018-03-01 2019-09-06 Общество С Ограниченной Ответственностью "Онкобокс" Способ и система для оценки клинической эффективности таргетных лекарственных средств
US11424011B2 (en) * 2018-12-10 2022-08-23 International Business Machines Corporation Analyzing knowledge graphs with unbounded insight generation
US20200222538A1 (en) * 2019-01-15 2020-07-16 International Business Machines Corporation Automated techniques for identifying optimal combinations of drugs
CN110241215B (zh) * 2019-07-03 2020-05-19 上海润安医学科技有限公司 一种用于检测甲状腺结节良恶性相关基因变异的引物及试剂盒
US11373281B1 (en) * 2021-02-23 2022-06-28 Qualcomm Incorporated Techniques for anchor frame switching
JP2024509887A (ja) * 2021-03-09 2024-03-05 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｅｐ３００分解剤および神経芽細胞腫におけるその使用
KR102421466B1 (ko) * 2021-10-06 2022-07-18 (주)이노베이션바이오 암 진단용 바이오마커 및 이의 용도
WO2023109876A1 (en) * 2021-12-16 2023-06-22 Edigene Therapeutics (Beijing) Inc. Biomarkers for colorectal cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909906A (pt) * 1998-04-03 2000-12-26 Triangle Pharmaceuticals Inc Sistemas, métodos e produtos de programa de computador para guiar a seleção de regimes de tratamento terapêutico
JP2006271385A (ja) * 2001-03-14 2006-10-12 Dna Chip Research Inc 大腸癌の予測方法
JP4222835B2 (ja) 2001-03-14 2009-02-12 株式会社Ｄｎａチップ研究所 癌の予測方法
US20060275747A1 (en) 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
ATE458003T1 (de) * 2001-12-07 2010-03-15 Novartis Vaccines & Diagnostic Bei prostatakrebs hochreguliertes endogenes retrovirus
JP2005519610A (ja) * 2002-03-13 2005-07-07 エフ．ホフマン−ラ　ロシュ　アーゲー 薬剤感受性規定因子の選択方法および選択された因子を用いた薬剤感受性の予測方法
JP2005038256A (ja) * 2003-07-16 2005-02-10 Jgs:Kk 有効因子情報選択装置、有効因子情報選択方法、プログラム、および、記録媒体
US8000982B2 (en) * 2004-02-17 2011-08-16 Body Bio, Inc. Network and methods for integrating individualized clinical test results and nutritional treatment
US7693857B2 (en) * 2005-11-17 2010-04-06 International Business Machines Corporation Clinical genomics merged repository and partial episode support with support abstract and semantic meaning preserving data sniffers
DK2508621T3 (en) * 2005-11-29 2015-01-12 Childrens Hosp Medical Center Optimization and individualization of drug selection and dosage
US20070198653A1 (en) * 2005-12-30 2007-08-23 Kurt Jarnagin Systems and methods for remote computer-based analysis of user-provided chemogenomic data
US7788259B2 (en) * 2006-07-21 2010-08-31 Microsoft Corporation Locating, viewing and interacting with information sources
US20080118576A1 (en) * 2006-08-28 2008-05-22 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2666921C2 (ru) * 2013-06-20 2018-09-13 Тайхо Фармасьютикал Ко., Лтд. СПОСОБ ПРЕДСКАЗАНИЯ ТЕРАПЕВТИЧЕСКОЙ ЭФФЕКТИВНОСТИ ИНГИБИТОРА PI3K/AKT/mTOR НА ОСНОВАНИИ ЭКСПРЕССИИ PHLDA1 ИЛИ PIK3C2B

Also Published As

Publication number Publication date
JP2012533103A (ja) 2012-12-20
CA2767659A1 (en) 2011-01-13
CN102473202A (zh) 2012-05-23
AU2010270227B2 (en) 2015-01-22
JP5773998B2 (ja) 2015-09-02
US20120136583A1 (en) 2012-05-31
ZA201200872B (en) 2012-10-31
AU2010270227A1 (en) 2012-02-09
EA021945B1 (ru) 2015-10-30
EP2452281B1 (en) 2019-10-02
NZ597655A (en) 2013-05-31
CA2767659C (en) 2020-10-20
ES2763899T3 (es) 2020-06-01
US10095829B2 (en) 2018-10-09
WO2011003911A1 (en) 2011-01-13
SG177571A1 (en) 2012-03-29
US20190005190A1 (en) 2019-01-03
DK2452281T3 (da) 2020-01-13
EP2452281A1 (en) 2012-05-16
IL217338A0 (en) 2012-02-29
CN102473202B (zh) 2015-11-25
SG10201403896XA (en) 2014-10-30
IL217338A (en) 2017-12-31

Similar Documents

Publication Publication Date Title
EA201200101A1 (ru) Способ прогнозирования эффективности лекарственных соединений для пациента
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1117858T1 (el) Ολιγονουκλεοτιδια για την προκληση αλλαγης στην αλληλουχια rna μοριου-στοχου παροντος σε ζωντανο κυτταρο
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
CY1121906T1 (el) Μεθοδος για τη θεραπεια της ατοπικης δερματιτιδας μεσω της χορηγησης ενος ανταγωνιστη toy il-4r
TR201902952T4 (tr) Dmd için ekson atlama bileşimleri.
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
BR112012020373A8 (pt) anticorpo isolado, célula, ácido nucleico isolado, método de identificação, de inibição da proliferação de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína tat419, de diagnóstico da presença de câncer e de distribuição de agente citotóxico
UA118090C2 (uk) Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
WO2011094335A3 (en) Microrna signatures predicting responsiveness to anti-her2 therapy
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
EA201201509A1 (ru) Фармацевтические составы, содержащие пиоглитазон и линаглиптин
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
EA201500207A1 (ru) Гетероароматические соединения в качестве ингибиторов втк
EP3106168A3 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
EA201490029A1 (ru) Соединения, ингибирующие металлоферменты
CR20120202A (es) Métodos y composiciones para tratar cáncer
EA201390347A1 (ru) Лечение заболеваний
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
EA201690782A1 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
WO2014066915A3 (en) Methods and compositions to produce ss-rnai activity with enhanced potency
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
EA201300129A1 (ru) Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM